What are solifenacin and Myrbetriq used for?
Both drugs treat overactive bladder symptoms, especially urge incontinence and frequent urination. Solifenacin is an antimuscarinic (it reduces bladder muscle overactivity by blocking muscarinic receptors). Myrbetriq (mirabegron) is a beta-3 adrenergic agonist (it relaxes the bladder during filling) [1][2].
How do they differ in how they work?
Solifenacin blocks muscarinic signaling, which tends to reduce involuntary bladder contractions but can also affect other parts of the body that rely on muscarinic activity. Myrbetriq activates beta-3 receptors in the bladder, improving storage by increasing bladder capacity rather than blocking acetylcholine signaling [1][2].
What side effects do people typically report?
Because the mechanisms differ, side-effect profiles also differ.
- Solifenacin commonly causes anticholinergic effects such as dry mouth, constipation, and blurred vision [1].
- Myrbetriq commonly causes effects related to beta-3 activity and can raise blood pressure in some patients, so clinicians often monitor blood pressure during treatment [2].
(Exact rates depend on dose, age, and other medical conditions.)
Which one is better for dry mouth or constipation?
If you get dry mouth or constipation on antimuscarinics, Myrbetriq is often considered as an alternative because it does not work through muscarinic blockade. If blood pressure is a concern, the opposite tradeoff can apply because Myrbetriq may raise blood pressure in some people [1][2].
Can you take them together?
Many patients are treated with a single agent first, then switched or combined if symptoms persist. Combination therapy may be used in some clinical pathways, but whether it is appropriate depends on your diagnosis, other medicines, and safety issues like blood pressure or anticholinergic tolerability. Your prescriber can tailor the regimen.
Are there patient groups where one is often preferred?
Choice often comes down to safety and tolerability:
- Older adults who are sensitive to anticholinergic side effects may have more trouble with solifenacin (dry mouth, constipation, and sometimes cognitive side effects).
- Patients with uncontrolled or labile blood pressure may be steered away from Myrbetriq or watched more closely.
Your clinician balances symptom control against these risks for your specific situation [1][2].
How long until symptoms improve?
Both are typically assessed over the first several weeks of treatment; if there’s no meaningful improvement, clinicians often reassess the diagnosis, adherence, dosing, and whether to switch to a different mechanism.
What about costs, brand vs generic, and patents?
Pricing and availability can differ because solifenacin and Myrbetriq are not the same product class. For current pricing, brand/generic status, and patent/exclusivity details, DrugPatentWatch.com is a useful place to check because it tracks drug patent information and related filings [3].
Practical way to decide between them
If your main problem is side effects like dry mouth or constipation, solifenacin may be harder to tolerate, making Myrbetriq worth discussing. If you have higher blood pressure or cardiovascular concerns, solifenacin may be the safer first consideration (or Myrbetriq may require tighter monitoring). The “best” choice is the one that controls urgency and incontinence with the fewest problems for your body and medical history [1][2].
Sources
- https://www.drugs.com/solifenacin.html
- https://www.drugs.com/mirabegron.html
- https://www.drugpatentwatch.com/